Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $142.1 million.

  • Mimedx's Cash & Equivalents rose 6000.16% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 6000.16%. This contributed to the annual value of $104.4 million for FY2024, which is 2733.66% up from last year.
  • Per Mimedx's latest filing, its Cash & Equivalents stood at $142.1 million for Q3 2025, which was up 6000.16% from $118.9 million recorded in Q2 2025.
  • Mimedx's 5-year Cash & Equivalents high stood at $142.1 million for Q3 2025, and its period low was $48.5 million during Q1 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $83.4 million (2021), whereas its average is $84.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 2426.77% in 2022, then soared by 11950.42% in 2025.
  • Quarter analysis of 5 years shows Mimedx's Cash & Equivalents stood at $87.1 million in 2021, then decreased by 24.27% to $66.0 million in 2022, then increased by 24.34% to $82.0 million in 2023, then rose by 27.34% to $104.4 million in 2024, then skyrocketed by 36.07% to $142.1 million in 2025.
  • Its Cash & Equivalents was $142.1 million in Q3 2025, compared to $118.9 million in Q2 2025 and $106.4 million in Q1 2025.